These models were also used to screen the delivery of two potentially therapeutic AD antibodies: an Aducanumab analogue (AduhelmTM; anti-Aβ antibody) and a novel anti-tau antibody, RNF5 (an anti-tau antibody that effectively reduces p-tau levels in an animal model with tau pathology). The gene discussed is MAPT; the disease is Alzheimer disease.